1. Home
  2. KDLY vs BIAF Comparison

KDLY vs BIAF Comparison

Compare KDLY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KDLY
  • BIAF
  • Stock Information
  • Founded
  • KDLY 2019
  • BIAF 2014
  • Country
  • KDLY United States
  • BIAF United States
  • Employees
  • KDLY N/A
  • BIAF N/A
  • Industry
  • KDLY
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • KDLY
  • BIAF Health Care
  • Exchange
  • KDLY NYSE
  • BIAF Nasdaq
  • Market Cap
  • KDLY 10.9M
  • BIAF 12.2M
  • IPO Year
  • KDLY 2024
  • BIAF 2022
  • Fundamental
  • Price
  • KDLY $13.86
  • BIAF $0.21
  • Analyst Decision
  • KDLY
  • BIAF Hold
  • Analyst Count
  • KDLY 0
  • BIAF 1
  • Target Price
  • KDLY N/A
  • BIAF N/A
  • AVG Volume (30 Days)
  • KDLY 5.3M
  • BIAF 880.8K
  • Earning Date
  • KDLY 05-08-2025
  • BIAF 05-15-2025
  • Dividend Yield
  • KDLY N/A
  • BIAF N/A
  • EPS Growth
  • KDLY N/A
  • BIAF N/A
  • EPS
  • KDLY N/A
  • BIAF N/A
  • Revenue
  • KDLY $2,470,466.00
  • BIAF $9,362,022.00
  • Revenue This Year
  • KDLY N/A
  • BIAF N/A
  • Revenue Next Year
  • KDLY N/A
  • BIAF $19.99
  • P/E Ratio
  • KDLY N/A
  • BIAF N/A
  • Revenue Growth
  • KDLY N/A
  • BIAF 269.68
  • 52 Week Low
  • KDLY $0.65
  • BIAF $0.16
  • 52 Week High
  • KDLY $5.25
  • BIAF $2.99
  • Technical
  • Relative Strength Index (RSI)
  • KDLY N/A
  • BIAF 32.36
  • Support Level
  • KDLY N/A
  • BIAF $0.19
  • Resistance Level
  • KDLY N/A
  • BIAF $0.24
  • Average True Range (ATR)
  • KDLY 0.00
  • BIAF 0.04
  • MACD
  • KDLY 0.00
  • BIAF -0.02
  • Stochastic Oscillator
  • KDLY 0.00
  • BIAF 11.72

About KDLY KINDLY MD INC

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: